Company intelligence / Profile preview
Accendatech
Tianjin, Tianjin, Chinaaccendatechusa.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Accendatech is a clinical-stage biopharmaceutical company developing innovative small molecule drugs targeting cancer stem cells, with a focus on brain cancers. Its lead candidate, ACT001, has completed Phase I and entered Phase II trials for indications such as diffuse intrinsic pontine glioma. The company also has several preclinical and early clinical programs targeting various cancers and fibrotic diseases. Clinical results to date suggest promise in treating difficult-to-treat brain tumors.
- Therapeutic areas
- OncologyPulmonology
- Modalities
- Small molecule drugsImmunomodulators
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Accendatech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Accendatech.